J Refract Surg. 2020 May 1;36(5):286-292. doi: 10.3928/1081597X-20200406-02.
To assess 3-year safety and efficacy of enhanced-fluence pulsed-light iontophoresis cross-linking (EF I-CXL) in patients with progressive keratoconus.
This prospective interventional pilot study included 24 eyes of 20 patients, with a mean age of 23.9 years (range: 15 to 36 years). Iontophoresis with riboflavin solution was used for stromal imbibition. The treatment energy was optimized at 30% (7 J/cm) and ultraviolet-A power set at 18 mW/cm × 6.28 minutes of pulsed-light on-off exposure, with a total irradiation time of 12.56 minutes. Uncorrected distance visual acuity (UDVA), corrected distance visual acuity (CDVA), corneal tomography, and corneal optical coherence tomography (OCT) at baseline and 1, 3, 6, 12, 24, and 3 years postoperatively were evaluated.
At 3 years, average UDVA decreased from 0.50 ± 0.10 to 0.36 ± 0.08 logMAR (P < .05), average maximum keratometry decreased from 52.94 ± 1.34 to 51.4 ± 1.49 diopters (D) (Delta: -1.40 ± 0.80 D; P < .05), average coma improved from 0.24 ± 0.05 to 0.12 ± 0.02 µm (P = .001), and symmetry index decreased from 4.22 ± 1.01 to 3.53 ± 0.90 D. Corneal OCT showed demarcation line detection at 285.8 ± 20.2 µm average depth in more than 80% at 1 month postoperatively.
The 3-year results of EF I-CXL showed satisfactory I-CXL functional outcomes, increasing the visibility and the depth of demarcation line closer to epithelium-off standard CXL. [J Refract Surg. 2020;36(5):286-292.].
评估强化脉冲光离子导入交联(EF I-CXL)在进行性圆锥角膜患者中 3 年的安全性和疗效。
本前瞻性干预性试点研究纳入了 20 名患者的 24 只眼,平均年龄为 23.9 岁(范围:15 至 36 岁)。使用核黄素溶液进行离子导入以实现基质浸润。优化治疗能量为 30%(7 J/cm),紫外线-A 功率设定为 18 mW/cm×6.28 分钟的脉冲光开/关照射,总辐照时间为 12.56 分钟。在基线和术后 1、3、6、12、24 和 3 年评估未矫正距离视力(UDVA)、矫正距离视力(CDVA)、角膜地形图和角膜光学相干断层扫描(OCT)。
3 年后,平均 UDVA 从 0.50±0.10 降至 0.36±0.08 logMAR(P<.05),平均最大角膜曲率从 52.94±1.34 降至 51.4±1.49 屈光度(D)(差值:-1.40±0.80 D;P<.05),平均彗差从 0.24±0.05 改善至 0.12±0.02 µm(P=.001),对称性指数从 4.22±1.01 降低至 3.53±0.90 D。角膜 OCT 在术后 1 个月时在超过 80%的部位检测到 285.8±20.2 µm 平均深度的分界线。
EF I-CXL 的 3 年结果显示出令人满意的 I-CXL 功能结果,增加了可见度和分界线深度,更接近上皮下标准 CXL。[J Refract Surg. 2020;36(5):286-292.]。